Cure My Disease

Don't miss your cure!

 Log in / Sign up

New PET tracer targets ACP3 to spot prostate cancer

NCT ID NCT07830212

NEW Diagnosis Sponsor: Yong He Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 21, 2026 · Last updated Sep 21, 2026

Summary

Researchers are testing a new PET imaging agent called [68Ga]Ga-OncoACP3 that targets a protein called ACP3, which is found in prostate cancer cells. The study enrolls 50 men with suspected or confirmed high-risk prostate cancer, or suspected recurrence after treatment. Each participant receives a single intravenous injection of the imaging agent and then undergoes a PET/CT scan about an hour later. The study measures how well the scan detects cancer lesions and compares it with standard PSMA PET imaging in some participants.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a radioactive imaging agent called [68Ga]Ga-OncoACP3 that targets prostate acid phosphatase (ACP3)
What this could lead to
If it works, this imaging could offer another way to find prostate cancer lesions, especially when standard PSMA PET scans miss them.
What could go wrong
This is a small, single-center study. The imaging agent may not detect lesions reliably, and results might not apply to all prostate cancer patients or to other hospitals.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 90 years

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 1\. Voluntary participation and signed written informed consent before any study-specific procedures; 2. Male, aged 18 to 90 years; 3. Clinically suspected high-risk, histologically confirmed, or suspected recurrent prostate cancer after treatment; 4. Willing and able to comply with scheduled visits, treatment plans, laboratory tests, and other study-related procedures; 5. Expected survival time greater than 6 months; 6. Participants' partners agree to use reliable contraceptive measures (such as abstinence, sterilization surgery, oral contraceptives, injectable medroxyprogesterone acetate, or subdermal implants) during the study and for at least 6 months after the last dose of study drug. Exclusion Criteria: * 1\. Known or suspected allergy to \[68Ga\]Ga-OncoACP3 injection or any of its excipients; 2. Any severe unstable disease (e.g., severe cardiac, pulmonary, hepatic, or renal insufficiency) that, in the investigator's judgment, makes the participant unsuitable for the study; 3. Inability to complete PET/CT examination, including inability to lie flat, claustrophobia, or radiophobia; 4. Poor compliance or any other condition that, in the investigator's judgment, makes the participant unsuitable for the study; 5. Prior use of a radiopharmaceutical within less than 10 physical half-lives before study drug administration; 6. Currently participating in or planning to participate in any drug or device clinical trial during the study period.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Prostate cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer prostate neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Prostate cancer Prostatic neoplasms

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Zhongnan Hospital of Wuhan University

    Wuhan, Hubei, 430071, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.